Ken Nenglong: Bringing China's Innovative Biomedicine to The World's Doors

original title: Kennenglong: Bringing China's innovative biological medicine to the door of the world
pictured is Dr Yan Xiaoqiang (right), chief scientific officer of the "three-person group" of the Kenn-long think tank, Dr Huang Yuliang (centre), chief executive officer, and Dr Tang Kaiyang, chief medical officer (left). On the afternoon of September 4, 2014, in the spacious and bright office building of Beijing Longxing Biopharmaceutical Co., Ltd in Beijing Yizhuang Economic Development Zone, experts and clinicians from top cancer, immunology, liver disease and hematology, as well as scientists from the domestic biopharmaceutical industry, were not only among those who came to participate in Longxing Bio's parent company, Jian Jian The 10th anniversary celebration of nenglong biopharmaceutical company, at the same time, is also for The world's second phase of clinical completion of the Independent Research and Development of The Bergsing (F-627) and the launch of the world's first biopharmaceutical Pronapavilion (F-652) in the United States, the "Beijing International Biopharmaceutical Development Seminar." Dr David L Lacey, chairman of the scientific advisory board of The onset of The Ronon Corporation and a former senior vice president of research and development at Amgen, told Science Daily that biopharmaceuticals are growing rapidly in the world, with major multinationals investing in research and development, and biopharmaceuticals are becoming the mainstream of the world's pharmaceutical industry At present, the world can do the Pronating (F-652) only the Kenneng Long family, from Kennlong body he saw China's growing biological drug innovation strength and ability Beijing Zhongguancun Management Committee Xuan hong deputy director of this praise, the development of the biopharmaceutical industry in China has a huge market demand, Zhongguancun has been looking forward to Jiannenglong such an innovative enterprise to join, he said passionately, "We fancy the team combination of Kenneng long company, from the moment they came here three years ago, I believe that these people can do great things!" In an interview with Science daily, Dr Tang Kaiyang, chief medical officer of Kennlong, admitted, "Since the company started its business ten years ago, all the way to experience the biopharmaceutical innovation company all kinds of sweet and sour bitter, can achieve today's achievements, we really belong to the lucky ones!" Since the first new biotechnology drug gene recombinant artificial insulin was launched in 1982, the development of biopharmaceuticals is only more than 20 years old, but it has brought two surprises to the world: first, to promote the rapid development of medical standards; In 2013, six of the top 10 drugs sold globally were biologics "The development of biopharmaceuticals is aggressive and is seen as a sunrise industry in global medicine, which is why Kenntron has been working to develop bio-innovative drugs since its inception," Dr Tang said. Keneken long think tank "three-person group" Kenn-long biotechnology company was founded in 2004, by the United States back to the sea jointly created The current CEO, Dr Huang Yuliang, has more than 20 years of experience in biomedical processes, plant construction operations and company management Dr Yan Xiaoqiang, who has been engaged in the molecular mechanism research of human diseases, has established an exploratory model for the internationalization of Chinese medicine and the study of the molecular mechanism of Chinese medicine, and is now the chief scientific officer of Kennlong Corporation Dr Tong Kaiyang, Chief Medical Officer, is familiar with global drug policy and regulations and is unique in the field of drug clinical and registration. "We all have an international background and years of experience in their respective fields, and we have similar ideas for biomedical innovation and new drug development, and the key is that we all want to do something, " Mr Tang recalls The company chose biomolecular drugs or research and development hot spot, because the scale of antibody drugs production, the need to invest also large, and considering that the research and development of this kind of research and development company to small-scale growth, fusion protein drug dossing dose is not high, so, the company designed to recombine protein drugs as the starting point of the development strategy. It is in this research and development approach that Kenntron has developed the core technology of the new Di-Kine new drug with patented technology, and successfully launched a series of innovative biopharmaceuticals in the clinical and pre-clinical stages Among them, Bergsting (F-627) for the treatment of cancer chemotherapy patients with granulocytic cell reduction, the current international multi-center phase II clinical into-the-community has been completed, the domestic phase II clinical study is under way; Cracking the "three mountains" of biopharmaceutical research and development, like chemical drug research and development, biopharmaceutical research and development there is a risk of capital, talent and clinical failure, which is the "three mountains" of the pressure that biopharmaceutical enterprises are facing together. In the ten years since the company was founded, Kennlong not only launched a new generation of new class 1 drug Begsting (F-627), also has the world's first class of new drug Pronating (F-652), is there any way to beat the 'three mountains'? Hearing the reporter's question, Mr Tong laughed, saying, "It's true that there aren't many research and development programs that can really complete the FDA clinical trials." "There was a Chinese biopharmaceutical investment who said that it was a great reason to be able to send an NDA (new drug application) to the FDA in his lifetime." "Don't look at everyone has taken the drug to the FDA to declare clinical, the whole of China is currently in the FDA to do NDA really few people," Tang said It's too hard to do medicine! From the experience of Ken-Long in the past, the most worrying of these years is the first and fort about the issue of money Drug research and development funds have to keep up, to continue to raise funds, all over the world to talk about investment. "The biggest advantage of Kenneng Long is that we have the 'real guy' in our hands, which is our core technology, investors are optimistic about our portfolio, our research and development, and willing to follow up." KenNlong's name as 'TOP10, the most investment-value enterprise in China's healthcare industry in 2012, illustrates this point," Tang said. In 2011, Kennlong established Beijing Longxing Biopharmaceutical Co., Ltd in Beijing In order to industrialization base construction, the company visited many domestic science and technology parks, and finally with the help of Zhongguancun's equity incentive policy dividends for biopharmaceutical enterprises, Ken Nenglong applied to Beijing's major scientific and technological achievements transformation and industrial co-ordination project approved projects Tang Kaiyang said with emotion, Zhongguancun Development Group gave us timely support, but also contributed to our industrial base settled in Beijing Daxing Yizhuang. In the talent strategy, Kenyon has exhausted the best professionals in the global network to form its own strategy and research and development team, becoming one of the magic tricks for its research and development to be rapid and successful, that is, with the experience and strength of the world's leading figures in the biological industry, stand at the forefront of technology research and development. Dr Lacey was senior vice president of Amgen USA, where he led a team of 1,200 people in more than 100 preclinical and clinical research programs in the fields of blood, oncology, inflammation, metabolic diseases and neuroscience Speaking about participating in the experience of Kennelong, Dr Lacey praised the company's 16-word culture of 'science, efficiency, enthusiasm, seriousness, collaboration, respect, health, happiness', which he said not only represents the core values of Kennelong, but also gives people a sense of the creative potential and spiritual connotations of these young entrepreneurs who have returned from the United States to start their businesses in China "The development and intellectual contribution of top foreign clinicians, as well as fellow experts, cannot be ignored In the main speakers at the Beijing International Symposium on Innovative Biopharmaceutical Development, the reporter saw the name, Dr John Glapy, from the UCLA Comprehensive Cancer Center, who has a deep knowledge of breast cancer, lymphoma and hematology; Dr Marcel Brink, current director of the haematology department of the Sloan-Kettering Cancer Center and director of the bone marrow transplant center, is a research medicine specialist..." We are lucky to be able to invite these world-class experts to give our research and development program support and guidance.